InMed Pharmaceuticals (INM)
(Delayed Data from NSDQ)
$0.26 USD
-0.01 (-3.00%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.27 +0.01 (1.93%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for InMed Pharmaceuticals Inc falls in the month of June.
All items in Millions except Per Share data.
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 9 | 6 | 7 | 6 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 2 | 2 | 0 | 0 |
Other Current Assets | NA | 1 | 1 | 1 | 0 |
Total Current Assets | NA | 11 | 10 | 8 | 6 |
Net Property & Equipment | NA | 1 | 1 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 2 | 2 | 1 | 1 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 14 | 13 | 10 | 8 |
Liabilities & Shareholders Equity | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 2 | 2 | 2 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 1 | 0 | 0 |
Total Current Liabilities | NA | 2 | 3 | 2 | 2 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 2 | 4 | 2 | 2 |
Shareholders Equity | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 78 | 71 | 61 | 53 |
Capital Surplus | NA | 36 | 32 | 22 | 18 |
Retained Earnings | NA | -101 | -93 | -75 | -65 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 12 | 9 | 7 | 6 |
Total Liabilities & Shareholder's Equity | NA | 14 | 13 | 10 | 8 |
Total Common Equity | 0 | 12 | 9 | 7 | 6 |
Shares Outstanding | 8.90 | 3.30 | 0.60 | 0.30 | NA |
Book Value Per Share | 0.00 | 3.66 | 15.13 | 24.60 | 0.00 |
Fiscal Year End for InMed Pharmaceuticals Inc falls in the month of June.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 8 | 10 | 7 | 9 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 1 | 1 | 1 | 2 |
Other Current Assets | NA | 1 | 1 | 0 | 1 |
Total Current Assets | NA | 10 | 12 | 8 | 11 |
Net Property & Equipment | NA | 1 | 1 | 1 | 1 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 2 | 2 | 2 | 2 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 13 | 15 | 11 | 14 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 1 | 1 | 1 | 2 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 2 | 2 | 1 | 2 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 1 | 1 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 2 | 2 | 1 | 2 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 81 | 80 | 78 | 78 |
Capital Surplus | NA | 38 | 38 | 36 | 36 |
Retained Earnings | NA | -107 | -105 | -104 | -101 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 11 | 13 | 10 | 12 |
Total Liabilities & Shareholder's Equity | NA | 13 | 15 | 11 | 14 |
Total Common Equity | 0 | 11 | 13 | 10 | 12 |
Shares Outstanding | 8.90 | 6.30 | 5.60 | 3.30 | 3.30 |
Book Value Per Share | 0.00 | 1.76 | 2.28 | 2.90 | 3.66 |